Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence
American Journal of Cardiovascular Drugs · 07.08.2026
DOI: 10.1007/s40256-026-00818-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 07.08.2026. Verfasst von Gianluigi Savarese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Short-term studies have demonstrated that single-pill combinations (SPCs) improve adherence, reduce hypertension-related complications, and lower costs; however, long-term benefits remain unclear. This study compared adherence, healthcare resource utilization (HCRU), and costs over 11 years in patients treated with SPCs versus free-pill combinations (FPCs) of antihypertensive drugs in routine Italian practice.
Methods
We analyzed a large administrative dataset (2010–2022) covering approximately 7 million Italian citizens. Adults initiating perindopril (PER)-based SPC or FPC with amlodipine and/or indapamide were included. PER-based therapies were selected because their SPCs were among the first marketed in Italy, allowing for extended follow-up. Adherence was measured by proportion of days covered (PDC), with high adherence defined as PDC ≥ 80%.
Results
Among 24,476 patients (mean age: 64.6 years; 59.7% male), 92.6% received SPCs, and 6.0% FPCs. High adherence was observed in 75.5% of SPC users compared with 32.0% of FPC users. SPC users had fewer all-cause hospitalizations and outpatient visits (both p < 0.001). Average annual healthcare costs were €242.96 lower for SPC users (95% CI €55.03–€430.89; p < 0.05), with significant reductions in costs related to all-cause and cardiovascular-related hospital admissions ( p < 0.001).
Conclusions
In this long-term, real-world study, SPC use was associated with better adherence, reduced HCRU, and lower healthcare costs compared with FPC regimens. These economic benefits were evident within 1 year and may yield substantial long-term savings for national health systems, given the high prevalence and chronic nature of hypertension. Graphical abstract
Autor:innen und Institutionen
- Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
- Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. ana.vintila@umfcd.ro.
- Internal Medicine and Cardiology Department, Colţea Clinical Hospital, Bd. I.C. Brătianu no. 1-3, 030171, Bucharest, Romania. ana.vintila@umfcd.ro.
- CliCon S.r.l. Società Benefit Health, Economics and Outcomes Research, Bologna, Italy.
- Inserm U1094, IRD UMR270, University of Limoges, CHU Limoges, Centre of Clinical and Research Data, EpiMaCT, OmegaHealth, Limoges, France.
- Medical University of Gdansk, Gdansk, Poland.
Zitieren
APA
Savarese, G., Vintila, A. M., Degli Esposti, L., Dovizio, M., Magne, J., Nugnes, M., Veronesi, C., Wolf, J., & Masi, S. (2026). Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-026-00818-4
Vancouver
Savarese G, Vintila AM, Degli Esposti L, Dovizio M, Magne J, Nugnes M, et al. Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence. American Journal of Cardiovascular Drugs. 2026. doi:10.1007/s40256-026-00818-4
BibTeX
@article{Savarese2026,
author = {Savarese, Gianluigi and Vintila, Ana-Maria and Degli Esposti, Luca and Dovizio, Melania and Magne, Julien and Nugnes, Marta and Veronesi, Chiara and Wolf, Jacek and Masi, Stefano},
title = {Adherence and Healthcare Costs Associated with Single-vs Free-Pill Combination of Perindopril-Based Antihypertensive Medications: An 11-Year Follow-Up, Real-World Evidence},
journal = {American Journal of Cardiovascular Drugs},
year = {2026},
doi = {10.1007/s40256-026-00818-4}
}
EUVIMED